Literature DB >> 18497078

Specific properties of a C-terminal truncated androgen receptor detected in hormone refractory prostate cancer.

Gaëlle Lapouge1, Gemma Marcias, Eva Erdmann, Pascal Kessler, Marion Cruchant, Sebastian Serra, Jean-Pierre Bergerat, Jocelyn Céraline.   

Abstract

Mutations in the human androgen receptor (AR) gene that lead to C-terminus truncated AR variants are frequently detected in prostate cancer (PC). These AR variants lack both the ligand-binding domain (LBD) and the AF-2 region. The aim of this study was to delineate the alternative mechanisms that lead to the activation of such AR variants as they are unresponsive to hormone stimulation, and to outline consequences of the loss of the LBD/AF-2 region on their functional properties. By using an MMTV-luciferase reporter construct and LY294002, UO126, or ZD1839, inhibitor of PI3K, MEK1/2, and EGFR signaling pathway respectively, we demonstrated that phosphorylation was required for full transcriptional activities of one these AR variants, the Q640X mutant AR. Western-blot analyses confirmed that these inhibitors affect the phosphorylation status of this AR variant. Furthermore, studies of the intranuclear colocalization of the Q640X AR with cofactors, such as CBP, GRIP-1, and c-Jun, reveal that the transcriptional complex that forms around the mutant AR is different to that formed around the wild type AR. We demonstrated that CBP and c-Jun are highly recruited by the mutant AR, and this leads to an unexpected activation of AP-1, NFAT, and NFkappaB transcriptional activities. Similar enhanced activities of these transcription factors were not observed with the wild type AR. The importance of the LBD/AF-2 for the regulation of AR transcriptional activities, the impact of the presence of such AR variants on PC cells proliferation and survival, and on progression to androgen independence are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18497078     DOI: 10.1007/978-0-387-69080-3_53

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  13 in total

1.  Inhibition of IGF-1R diminishes transcriptional activity of the androgen receptor and its constitutively active, C-terminally truncated counterparts Q640X and AR-V7.

Authors:  Friedemann Zengerling; Anca Azoitei; Alexander Herweg; Florian Jentzmik; Marcus V Cronauer
Journal:  World J Urol       Date:  2015-08-29       Impact factor: 4.226

2.  AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells.

Authors:  Wolfgang Streicher; Friedemann Zengerling; Martin Laschak; Wolfgang Weidemann; Michael Höpfner; Andres J Schrader; Florian Jentzmik; Mark Schrader; Marcus V Cronauer
Journal:  World J Urol       Date:  2012-02-24       Impact factor: 4.226

3.  Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.

Authors:  Michael C Byrns; Rebekka Mindnich; Ling Duan; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2012-01-12       Impact factor: 4.292

4.  Androgen receptor abnormalities in castration-recurrent prostate cancer.

Authors:  Lucas P Nacusi; Donald J Tindall
Journal:  Expert Rev Endocrinol Metab       Date:  2009-09-01

5.  Anti-androgen resistance in prostate cancer cells chronically induced by interleukin-1β.

Authors:  Julia A Staverosky; Xin-Hua Zhu; Susan Ha; Susan K Logan
Journal:  Am J Clin Exp Urol       Date:  2013-12-25

Review 6.  On the origins of the androgen receptor low molecular weight species.

Authors:  Maria Mudryj; Clifford G Tepper
Journal:  Horm Cancer       Date:  2013-07-17       Impact factor: 3.869

7.  Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells.

Authors:  Donald J Vander Griend; Lizamma Antony; Susan L Dalrymple; Yi Xu; S Brogger Christensen; Samuel R Denmeade; John T Isaacs
Journal:  Mol Cancer Ther       Date:  2009-05-05       Impact factor: 6.261

8.  Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells.

Authors:  Félicie Cottard; Irène Asmane; Eva Erdmann; Jean-Pierre Bergerat; Jean-Emmanuel Kurtz; Jocelyn Céraline
Journal:  PLoS One       Date:  2013-05-02       Impact factor: 3.240

9.  Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells.

Authors:  Yuantong Tian; Lijing Zhao; Ye Wang; Haitao Zhang; Duo Xu; Xuejian Zhao; Yi Li; Jing Li
Journal:  Asian J Androl       Date:  2016 Jul-Aug       Impact factor: 3.285

10.  AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression.

Authors:  Yuantong Tian; Lijing Zhao; Haitao Zhang; Xichun Liu; Lijuan Zhao; Xuejian Zhao; Yi Li; Jing Li
Journal:  Diagn Pathol       Date:  2014-02-26       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.